Research reviewed: October 2026
New degenerative myelopathy research is bringing scientists closer to understanding how the disease develops and how it might eventually be treated. Recent studies have investigated gene-silencing therapy, immune-system activity, abnormal protein accumulation, and ways to improve diagnosis and disease management.
One of the most significant developments came in February 2026, when researchers published the results of an experimental treatment designed to reduce production of the SOD1 protein associated with canine degenerative myelopathy (DM).
Other studies are exploring the inflammatory changes associated with DM and whether specific treatments could help protect nerve cells.
But an important distinction remains: There is currently no established treatment proven to stop or reverse degenerative myelopathy in dogs.
Here’s what recent research has found, which treatments remain experimental, and what these discoveries could mean for dogs living with DM.
What Are the Latest Advances in Degenerative Myelopathy Research?
Recent studies are investigating several different approaches to understanding and potentially treating DM.
| Research area | Recent findings | What it means today |
|---|---|---|
| Gene-silencing therapy | Experimental treatment reduced SOD1 expression in a small canine pilot study | Promising early results; clinical benefit not established |
| Immune-system research | Researchers identified inflammatory signaling changes in blood and spinal cord tissue | Helps explain disease mechanisms |
| Protein stabilization | Laboratory studies investigated compounds that affect abnormal SOD1 proteins | Preclinical research, not a proven treatment |
| Genetic research | Studies continue examining SOD1 variants and disease susceptibility | Helps clarify inherited risk, not definitive diagnosis |
| Diagnosis and prognosis | Research examines biomarkers and concurrent spinal conditions | May improve future assessment and study design |
| Rehabilitation and stem cells | Small studies have examined intensive rehabilitation combined with experimental interventions | Findings need larger, controlled studies |
These advances represent different stages of research. Some have been tested in dogs with DM, while others remain limited to laboratory experiments.
1. Gene-Silencing Therapy: A Major Development in 2026
One of the most notable recent developments in degenerative myelopathy research involves a treatment designed to reduce production of SOD1, a protein strongly associated with the disease.
The SOD1 gene normally helps produce an enzyme involved in protecting cells from certain forms of damage. However, specific mutations are associated with abnormal SOD1 protein folding and accumulation, which can contribute to nerve-cell damage.
Researchers have been investigating whether reducing SOD1 production could become a treatment strategy.
What did the 2026 study find?
A study published in the Journal of Veterinary Internal Medicine in February 2026 evaluated an experimental gene-silencing approach called U1 Adaptor therapy.
Researchers studied seven healthy dogs and five dogs with DM at different stages. Four dogs with early-stage DM received repeated injections into the fluid surrounding the spinal cord over a period of up to 10 months.
The treatment reduced SOD1 RNA expression in spinal cord tissue near the injection site to a median of 37% of normal levels. Researchers also reported that the treatment was generally well tolerated within the small study.
This was an important demonstration that SOD1 production could be reduced in dogs using this approach.
Does this mean scientists have found a treatment for DM?
Not yet.
The study was designed primarily to investigate safety and whether the treatment could reach and affect its biological target.
Reducing SOD1 expression is not the same as proving that dogs walk longer, experience slower disease progression, or survive longer.
The study involved a small number of dogs, and larger controlled trials are needed to establish whether the treatment provides meaningful clinical benefits.
Researchers also identified the need for improved administration methods.
Still, the findings represent an important step toward developing therapies that target a biological mechanism associated with DM rather than focusing solely on supportive care.
Read the study: Development and Pilot Testing of U1 Adaptor Therapy Targeting SOD1 Expression for Dogs With Degenerative Myelopathy (2026)
2. Immune-System Research: Understanding Inflammation in DM
Scientists are also investigating the role of inflammation in degenerative myelopathy.
A March 2026 study published in Scientific Reports examined immune-related changes in the blood and spinal cord tissue of dogs with DM.
Researchers found changes in several inflammatory signaling molecules, including increased expression of certain immune-related markers in peripheral blood.
They also identified changes in spinal cord tissue associated with astrocytes, cells that support the nervous system and can participate in inflammatory responses.
Why does this matter?
The findings suggest that immune-system signaling and inflammation are involved in the disease process.
However, the study also found limited evidence of immune cells entering the spinal cord from the bloodstream. This suggests that systemic immune activity may contribute to spinal inflammation without necessarily being a major direct driver of nerve degeneration.
Understanding these mechanisms may help researchers identify additional treatment targets.
Could anti-inflammatory treatments help?
That has not been established by this research.
Identifying inflammatory activity does not mean that conventional anti-inflammatory medications, immune supplements, or other immune-modifying treatments will slow DM.
More research is needed to determine which inflammatory changes contribute to disease progression and whether modifying them would improve outcomes.
Read the study: Analysis of Immune-Related Alterations in Blood and Spinal Cord of Canine Degenerative Myelopathy (2026)
3. SOD1 Protein Research: Can Abnormal Protein Accumulation Be Reduced?
Another important research direction involves understanding how mutated SOD1 proteins behave.
In dogs with SOD1-associated DM, abnormal protein folding and accumulation are thought to contribute to damage within the nervous system.
Rather than directly reducing SOD1 production, some researchers are investigating whether abnormal proteins can be stabilized or prevented from accumulating.
What did researchers discover in 2025?
A 2025 study used a laboratory-based system to investigate how normal and mutated canine SOD1 proteins interact.
Researchers examined the effects of proteins and compounds involved in SOD1 stability, including copper chaperone for SOD1 (CCS) and derivatives of a compound called ebselen.
The findings provided additional insight into differences between normal and mutated SOD1 proteins and potential approaches to stabilizing their structure.
This work is important because understanding how abnormal proteins behave may help researchers identify compounds worth testing in future studies.
Is this a treatment dogs can receive?
No.
These findings came from laboratory experiments rather than clinical trials demonstrating improved outcomes in dogs with DM.
A compound that changes protein behavior in a laboratory model may not produce the same effect in a living animal.
Safety, dosage, delivery to the nervous system, and actual clinical benefit would all need to be established.
4. Riluzole Clinical Trials: Can an Existing ALS Drug Help Dogs With DM?
Riluzole is a medication used in the treatment of amyotrophic lateral sclerosis (ALS) in humans.
Because canine degenerative myelopathy shares certain genetic and pathological features with forms of ALS, researchers have investigated whether riluzole could offer benefits for dogs with DM.
Earlier safety research helped establish dosing approaches for dogs, leading to a randomized, blinded, placebo-controlled clinical trial.
The trial began in December 2023 and involves veterinary research institutions including the University of Missouri, North Carolina State University, The Ohio State University, and Tufts University.
Has riluzole been proven effective for DM?
No published clinical efficacy result establishing that riluzole slows canine DM was verified for this October 2026 review.
The research remains important, but participation in a clinical trial or successful completion of preliminary safety testing does not establish that a drug is effective.
Pet parents should not interpret riluzole’s use in human ALS as evidence that it will produce the same benefits in dogs.
Riluzole should not be given to a dog outside appropriate veterinary supervision.
Research update: Cure4DM: Degenerative Myelopathy Research and Riluzole Trial Information
Editor’s note: This is a research-program update rather than a newly published peer-reviewed efficacy study. Trial results should be added when they become available.
5. Stem Cell Therapy and Intensive Rehabilitation: What Does the Evidence Show?
Stem cell therapy has attracted attention as a possible treatment for neurological conditions, including DM.
A 2023 study published in Frontiers in Veterinary Science examined intensive neurorehabilitation combined with allogeneic mesenchymal stem cell transplantation.
The study included 13 nonambulatory dogs with presumptive DM.
Eight dogs received intensive rehabilitation combined with stem cell treatment, while five received a different rehabilitation protocol.
Researchers reported a mean survival time of 438 days in the intensive rehabilitation and stem cell group, compared with 274 days in the comparison group.
These findings are interesting, but they require careful interpretation.
Did stem cells extend survival?
The study cannot establish that stem cells alone caused the difference.
The groups received different rehabilitation protocols as well as different stem cell treatment exposure. The study was also small.
Because multiple interventions differed between groups, the individual contribution of stem cells cannot be isolated confidently.
Larger studies with appropriate controls are needed before stem cell transplantation can be considered an established treatment for DM.
Read the study: Intensive Neurorehabilitation and Allogeneic Stem Cells Transplantation in Canine Degenerative Myelopathy (2023)
6. Genetic Research: What Does SOD1 Testing Actually Tell Us?
Research into SOD1 mutations has substantially improved our understanding of degenerative myelopathy.
However, one of the most important points for dog owners is that having a genetic variant associated with DM does not automatically mean a dog has the disease or will develop symptoms.
The relationship between genotype and clinical disease is complicated by factors such as age-related incomplete penetrance.
In other words, some dogs with a high-risk genetic profile may never develop clinical signs.
What are researchers investigating?
Research continues to examine how frequently disease-associated SOD1 variants occur in different breeds and how genetic risk relates to actual disease development.
For example, a 2026 report examined the frequency of a DM-associated SOD1 variant in Irish Wolfhounds.
Breed-specific research can improve understanding of inherited risk and inform responsible breeding decisions, but it does not make genetic testing a stand-alone diagnostic tool.
Read the study: Genotype and Allele Frequencies of Canine Degenerative Myelopathy-Associated SOD1 Gene Variant in Irish Wolfhound Dogs (2026)
Can a DNA test diagnose DM?
Not by itself.
Genetic testing can identify dogs carrying a disease-associated variant, but veterinarians must also consider neurological findings and other conditions that can cause similar symptoms.
DM remains challenging to diagnose definitively during life. A presumptive diagnosis generally involves clinical assessment, supportive genetic information, and exclusion of other possible causes.
This distinction is particularly important when a dog develops weakness or coordination problems that might have a treatable explanation.
7. Research Into Other Spinal Conditions Is Improving Our Understanding of DM
Dogs suspected of having degenerative myelopathy may also have other spinal disorders.
This can complicate both diagnosis and predictions about how quickly mobility will decline.
A 2025 exploratory study examined 39 dogs with compatible neurological signs and a high-risk SOD1 genotype.
Researchers compared dogs with and without concurrent thoracolumbar intervertebral disc protrusion.
They did not find a statistically significant difference in survival or progression to loss of walking ability between the groups.
Why is this important?
The study highlights how complicated DM assessment can be.
A dog may have both genetic risk for DM and structural spinal changes. Determining which condition is responsible for specific symptoms requires careful neurological evaluation.
The findings also illustrate why small observational studies must be interpreted cautiously. The absence of a statistically significant difference does not prove that concurrent spinal disease never affects an individual dog.
8. Biomarker Research: Could DM Become Easier to Diagnose?
One of the challenges in degenerative myelopathy is that several other neurological disorders can produce similar symptoms.
Researchers have investigated biomarkers, including neurofilament proteins, that may help identify or characterize nervous-system damage.
These proteins can be released when nerve fibers are injured or degenerate.
Some studies have investigated neurofilament measurements in dogs with neurological disorders, including their potential relevance to DM.
However, detecting nerve damage isn’t necessarily the same as identifying its cause.
Is there a reliable blood test for DM?
Not currently as a stand-alone, clinically established diagnostic test.
Neurofilament biomarkers may eventually help veterinarians distinguish certain neurological conditions, assess disease activity, or evaluate treatment responses.
But further validation is necessary before such testing can reliably confirm DM or replace the broader diagnostic process.
A 2024 study examining cerebrospinal fluid biomarkers across canine neurological disorders illustrates the ongoing work in this area.
Read the study: On the Utility of Cerebrospinal Fluid Biomarkers in Canine Neurological Disorders (2024)
9. What Does the Research Say About Physical Rehabilitation?
While scientists investigate treatments that might eventually modify the disease itself, physical rehabilitation remains an important part of supportive care.
Rehabilitation is intended to help dogs maintain function, strength, coordination, and participation in everyday activities for as long as possible.
A 2023 survey of veterinary neurologists and rehabilitation professionals found that most respondents routinely recommended exercise and physical rehabilitation for dogs with presumptive DM.
Common approaches included:
- Individualized home exercises
- Gait training
- Strength and balance activities
- Underwater treadmill therapy
- Assisted walking
- Mobility equipment when appropriate
However, the evidence must be interpreted carefully.
Rehabilitation may help preserve function and support quality of life, but available research does not establish that a specific exercise program reliably stops the underlying neurodegenerative process.
The intensity and type of activity should be adjusted to the dog’s disease stage, physical abilities, and any other health conditions.
Read the study: Diagnosis and Management of Dogs With Degenerative Myelopathy: A Survey of Neurologists and Rehabilitation Professionals (2023)
What Does the Latest DM Research Mean for Dog Owners?
It’s encouraging to see researchers investigating therapies that go beyond symptom management.
The 2026 gene-silencing study is particularly important because it demonstrated that researchers could directly influence SOD1 expression in dogs.
But the distinction between a promising experiment and an effective treatment matters.
Here’s where the evidence stands as of October 2026:
| Research question | Current answer |
|---|---|
| Is there a cure for DM? | No established cure |
| Can gene-silencing therapy reduce SOD1 expression? | Yes, in a small experimental canine study |
| Has gene silencing been proven to slow DM? | Not yet |
| Has riluzole been proven effective in dogs with DM? | Not established |
| Is stem cell therapy a proven treatment? | No |
| Can genetic testing confirm DM by itself? | No |
| Can rehabilitation help maintain function? | It is commonly recommended, with supportive but limited outcome evidence |
| Are researchers making progress? | Yes, particularly in disease mechanisms and experimental treatment development |
For families currently caring for a dog with DM, the most useful next step is to work with their veterinarian or rehabilitation professional on an individualized mobility plan.
That may include appropriate exercise, maintaining a healthy body condition, monitoring changes in strength and coordination, and introducing mobility aids when they become useful.
Research may change what is possible in the future. For now, practical supportive care remains essential.
What Should Dog Owners Watch for Next?
Several developments will be particularly important to follow:
Larger gene-silencing trials: Researchers need to determine whether reducing SOD1 expression translates into slower progression, longer mobility, or improved survival.
Published riluzole efficacy results: Controlled trial findings will help establish whether the medication provides a measurable benefit.
Better biomarkers: Reliable measures of disease activity could improve diagnosis and help researchers determine whether experimental treatments are working.
Improved genetic understanding: Research may help explain why some genetically susceptible dogs develop DM while others do not.
Controlled rehabilitation and treatment studies: Larger trials are needed to identify which interventions provide meaningful benefits.
The most important future breakthroughs won’t simply demonstrate changes in laboratory measurements. They’ll show whether dogs experience meaningful improvements in function, comfort, or disease progression.
Frequently Asked Questions About Degenerative Myelopathy Research
What is the newest treatment being researched for degenerative myelopathy in dogs?
One important recent development is U1 Adaptor gene-silencing therapy. A February 2026 pilot study demonstrated that the treatment could substantially reduce SOD1 expression in dogs. However, it has not been proven to slow disease progression or improve survival.
Is there a cure for degenerative myelopathy in 2026?
No. As of October 2026, there is no established treatment proven to cure, stop, or reverse canine degenerative myelopathy.
Can stem cell therapy reverse DM?
There is no convincing clinical evidence that stem cell therapy reverses DM. Small studies have examined stem cells combined with rehabilitation, but larger controlled studies are necessary.
Does riluzole work for dogs with degenerative myelopathy?
Riluzole has been investigated as a potential treatment, but clinical efficacy in dogs with DM has not been established.
Can a genetic test tell me if my dog has DM?
A genetic test can identify disease-associated SOD1 variants, but it cannot independently confirm a diagnosis. Some dogs with a high-risk genotype never develop symptoms, and other spinal conditions can produce similar neurological signs.
Can physical therapy slow degenerative myelopathy?
Physical rehabilitation may help maintain mobility and function, but strong evidence that it directly slows the underlying disease process remains limited. Programs should be individualized by veterinary professionals.
Why is degenerative myelopathy compared with ALS?
Canine DM shares certain genetic and pathological characteristics with forms of human amyotrophic lateral sclerosis, including abnormalities involving SOD1. These similarities make DM relevant to comparative neurological research, but the two conditions are not identical.
The Future of Degenerative Myelopathy Research
For decades, degenerative myelopathy research has focused on understanding why the spinal cord progressively loses function and whether that process can be interrupted.
Recent studies represent meaningful progress.
Researchers are now testing approaches that directly target SOD1 production, investigating immune signaling within the nervous system, and exploring ways to stabilize abnormal proteins.
These findings don’t yet offer a cure, but they provide a stronger scientific foundation for future treatments.
For dog owners, the most important message is one of hope. Promising research deserves attention, but experimental findings should never be mistaken for proven therapies.
Until effective treatments are established, helping dogs maintain mobility, comfort, and quality of life remains the priority.
Related Articles
Leave a Reply